TITLE OF PAPER: Genetic Variant rs1205 is Associated with COVID-19 Outcomes:
 The Strong Heart Study and Strong Heart Family Study.

AUTHORS: Best LG,^{1,2} Erdei E,³ Haack K,⁴ Kent JW Jr.,⁴ Malloy K,⁵ Newman DE,⁴
 O'Leary M,¹ O'Leary R,¹ Sun Q,⁶ Navas-Acien A,⁷ Franceschini N,⁸ and Cole SA,⁴

6

⁷ ¹ Epidemiology Division, Missouri Breaks Industries Research, Inc. Eagle Butte, SD,

8 USA ² Pathology Department, University of North Dakota, Grand Forks, ND, USA

⁹ ³Pharmaceutical Sciences, University of New Mexico - Albuquerque, Albuquerque, New

10 Mexico, USA. ⁴Population Health Program, Texas Biomedical Research Institute, San

11 Antonio, TX, USA. ⁵Center for American Indian Health Research, Department of

12 Biostatistics and Epidemiology, Hudson College of Public Health, University of

13 Oklahoma Health Sciences Center, Oklahoma City, OK, USA. ⁶Department of

Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA,

¹⁵ ⁷Department of Environmental Health Science, Mailman School of Public Health,

16 Columbia University, NY, New York, USA. ⁸Department of Epidemiology, University of

17 North Carolina at Chapel Hill, Chapel Hill, NC, USA.

18

19

20 Abstract:

- Background: Although COVID-19 infection has been associated with a number of
- 22 clinical and environmental risk factors, host genetic variation has also been associated
- with the incidence and morbidity of infection. The *CRP* gene codes for a critical
- component of the innate immune system and *CRP* variants have been reported
- 25 associated with infectious disease and vaccination outcomes. We investigated possible
- associations between COVID-19 outcome and a limited number of candidate gene
- variants including rs1205.
- 28 Methodology/Principal Findings: The Strong Heart and Strong Heart Family studies
- 29 have accumulated detailed genetic, cardiovascular risk and event data in geographically
- dispersed American Indian communities since 1988. Chi-square tests, logistic
- regression and generalized linear mixed models (implemented in SOLAR) were used in
- analysis. Genotypic data and 91 COVID-19 adjudicated deaths or hospitalizations from
- 2/1/20 through 3/1/23 were identified among 3,780 participants in two subsets. Among
- 21 candidate variants including genes in the interferon response pathway, APOE,
- *TMPRSS2*, *TLR3*, the HLA complex and the ABO blood group, only rs1205, a 3'
- ³⁶ untranslated region variant in the *CRP* gene, showed nominally significant association
- in T-dominant model analyses (odds ratio 1.859, 95%Cl 1.001-3.453, p=0.049) after
- adjustment for age, sex, center, body mass index, and a history of cardiovascular
- disease. Within the younger subset, association with the rs1205 T-Dom genotype was
- 40 stronger, both in the same adjusted logistic model and in the SOLAR analysis also
- 41 adjusting for other genetic relatedness.
- 42 Conclusion: A T-dominant genotype of rs1205 in the *CRP* gene is associated with
- 43 COVID-19 death or hospitalization, even after adjustment for relevant clinical factors
- 44 and potential participant relatedness. Additional study of other populations and genetic
- 45 variants of this gene are warranted.
- 46 Author summary:
- 47 Considerable inter-individual variability in COVID-19 clinical outcome has been noted
- 48 from the onset of this pandemic. Some risk factors, such as age, diabetes, obesity, prior
- 49 cardiovascular disease (CVD) are well established. The possibility of inherited, host
- 50 genetic risk factors has also been examined and a number validated in very large,
- 51 population based datasets. The present study leveraged on-going clinical surveillance
- of CVD and available genetic information in an American Indian population to
- 53 investigate potential host genetic contributors to COVID-19 morbidity and mortality.
- 54 Although the number of cases ascertained was relatively small, a novel variant in the C-
- reactive protein gene was found to be associated with COVID-19 outcome. This protein
- 56 constitutes a critical component of the innate immune system and *CRP* variants have
- 57 been reported associated with infectious disease and vaccination outcomes. Improved
- ⁵⁸ understanding of the pathophysiology of this infection may allow more targeted therapy.
- 59

60 Introduction

The ongoing pandemic of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infections has taken a devastating toll on American Indian, Alaskan Native (AI/AN) populations, with hospitalization and death rate ratios for COVID-19 (compared with White ethnicity) reported as 2.5 fold; and 2.1 fold, respectively.[1]

65 A number of demographic and clinical characteristics, such as male gender, socio-economic deprivation, diabetes, cardiovascular disease and obesity, have been 66 identified as risk factors for COVID-19 associated morbidity and mortality.[2] The 67 hypothesis that this increased burden of COVID-19 morbidity and mortality among 68 ethnic minorities is due to the increased prevalence of these co-morbidities in many 69 populations, has been considered; but the proportion of effect attributable to clinical co-70 morbidities may, be small.[2] In spite of considerable interest in possible host genetic 71 72 factors that influence the severity of COVID-19 among all patients, there have been few 73 reliably replicating studies in specific racial/ethnic groups.[3]

The expectation that ethnic disparities in COVID-19 outcomes are primarily driven by population specific behavioral or clinical burden of disease may have resulted in less interest in investigating genetic susceptibility among Al/AN communities. This is of importance for the possible identification of therapeutic targets and prevention strategies assisting Al/AN as well as other populations.

79 The Strong Heart Study (SHS) and allied Strong Heart Family Study (SHFS), comprise the largest, ongoing prospective epidemiological cohort study among 80 81 American Indians in 12 different Tribal communities located in Arizona, North and South 82 Dakotas, and in Oklahoma. These cohorts have the requisite genetic datasets and ongoing surveillance of medical records for cardiovascular disease (CVD) and risk 83 factors, including COVID-19, to also assess genetic contributions to COVID-19 death 84 85 and morbidity risks. The present results derive from a case/cohort analysis of SNPs reported associated with COVID mortality or morbidity in other populations. 86

87

88 Materials and Methods

89 Participants and Cohorts

The SHS/SHFS methodology and design has been described previously.[4,5] 90 Diabetes and hypertensive status were defined as previously;[6] and the dichotomous 91 CVD covariate indicates any history of myocardial infarction, coronary artery disease, 92 congestive heart failure, and atherosclerotic stroke and peripheral vasculature 93 disease.[7] While SHS/SHFS medical record surveillance of participants focuses on 94 ascertainment of outcome events and clinical risk factors related to CVD, in early 2020 95 ascertainment for COVID-19 was begun, with the recognition of a bidirectional 96 97 relationship between CVD and COVID-19 infection. The physicians conducting medical 98 records reviews identified COVID-19 as either a contributing or definitive factor in death

or hospitalization (disease severity). However, medical record review was triggered
 primarily by CVD related events (for ascertainment criteria, see Lee et al [4]) and a
 small number of other conditions, but not primarily by infections. Thus, the identified
 COVID-19 endpoint of hospitalization is probably under-reported, given the surveillance
 focus on CVD outcomes. However, all deaths associated with COVID-19 during the
 study period are included in this report.

The study period was 2/1/2020 through 3/1/2023, when medical record reviews 105 106 ascertaining COVID-19 outcomes were available. We included all participants alive on 107 2/1/2020 and identified outcome events (either COVID-19 death or hospitalization) 108 during follow-up. There were no specific ICD-9/10 codes used to identify relevant 109 morbid COVID-19 cases, but physician review of the medical record determined 110 COVID-19 case status based on immune measures and clinical diagnoses, with morbid events for review selected on the basis of standard SHS protocol to ascertain incident 111 CVD.[4] 112

113 Rationale for genetic variants selected

A PubMed literature search for candidate variants previously reported to be 114 115 associated with COVID-19 pathogenesis or clinical outcomes found previously 116 implicated genes in the interferon response pathway, [8,9] APOE, [10] TMPRSS2, [11] 117 TLR3.[9] ACE.[12] FURIN[13] and the human leukocyte antigen (HLA)[14,15] regions. We also included ABO blood group polymorphisms which have been among the most 118 119 consistently identified host factors influencing the COVID-19 phenotype.[16-18] The top 17 "hits" of of the Covid-19 Host Genetics Initiative Browser, round 7 identified 120 additional variants of interest.[19] 121

Thus our literature search developed a total of 73 plausible candidate variants and resulted in 21 polymorphisms that were available from the genetic resources of the SHS, albeit within two subsets of participants that were genotyped in SHS/SHFS substudies. The candidate SNPs and identifying, published references are found in Table 1.

127

Table 1. Variants genotyped, (associated genes) and allele frequency (AF), when the genotype is available.

Variant (gene)	RISK	SHFS	SHS	Literature
	ALLELE	AF of	AF of	citation
		risk	risk	
		allele	allele	
rs16944971 (FURIN)	С	0.01	NA*	[13,20]
rs7412 (APOE)	С	0.02	NA	[3,21]
rs1205 (CRP), alternate allele =T	С	0.49	0.46	[22-25]
rs3091244 (CRP)	G	0.31	NA	[26-28]

rs3093068 (CRP)	G	NA	0.01	[29,30]
rs1800947 (CRP)	С	NA	0.02	[23,25,29,31]
rs201253322 (IRF7)	С	NA	<0.001	[3,9]
rs116302758 (DPP4)	Т	NA	0.02	[11]
rs56179129 (DPP4)	С	NA	0.002	[11]
rs12329760 (TMPRSS2)	С	NA	0.20	[11,13,32]
rs150892504 (ERAP2)	С	NA	0.001	[33,34]
rs1800795 (IL-6)	G	NA	0.08	[23,35,36]
rs1799752 (ACE)	Insertion	NA	0.26	[3,13]
rs8176719 (ABO, O allele)	Insertion	NA	0.76	[16,37]
rs8176746 (ABO, B allele)	G	0.02	0.02	[38,39]
rs10735079 (OAS3)	A	NA	0.13	[40,41]
rs1405655 (NR1H2)	G	NA	0.45	[42]
rs1886814 (FOXP4-AS1)	A	NA	0.41	[40]
rs2109069 (DPP9)	G	NA	0.22	[41,42]
rs9380142 (HLA-G)	A	NA	0.32	[40,41]
rs111837807 (CCHCR1)	A	NA	0.20	[42,43]
rs2071351 (HLA-DPA1)	A	NA	0.08	[40]
rs529565 (ABO, intron variant)	A	NA	0.23	[40]
rs10774671 (OAS1)	A	NA	0.13	[40]
rs61667602 (LINC02210-CRHR1)	A	NA	0.06	[42]

130 * NA, Not available in this cohort

131

Although genotypes were derived from extensive microarray sources, no attempt was made to screen or identify variants of interest on the basis of genome-wide analysis of SHS microarray data.

The only exception to the qualification of previously identified association was the choice of *CRP* polymorphisms as explained below. This was felt to be justified due to the central role of CRP in the innate immune system and dramatic elevation during COVID-19 and other viral infections.[43]

139 C-reactive protein (CRP) levels are typically thought of as a biomarker for 140 inflammatory response and not as a pathogenetic factor, although inherited *CRP* 141 variants have been associated with, and thus possibly a modifying factor in some 142 infections[22,23] response to vaccination,[26] as well as other conditions such as 143 cancer[44,45] and pre-eclampsia.[46,47] For this reason, we selected 4 available 144 variants related to *CRP* expression for our analysis.

145 Laboratory methods and considerations

Clinical, anthropometric and laboratory measures are reported as obtained from the most recent SHS exam prior to the study period. Laboratory methodology for determination of serum creatinine,[48] HgbA1c[49] and high sensitivity C-Reactive Protein (hsCRP)[50] have been reported previously

The SHFS [5] participants were genotyped with the Illumina Human Cardio-Metabo BeadChip microarray (Illumina, San Diego, CA), incorporating approximately 200,000 single nucleotide polymorphisms (SNPs) in loci previously identified as significantly associated with metabolic and CVD traits.[51] These genotypes were generated exclusively from SHFS participants <u>without</u> diabetes mellitus during exams between 1997-2003. Further details related to quality filters and data preparation have been published.[50]

The SHS participants were genotyped using the Illumina Infinium Multi-Ethnic Global-8 vs1. Quality control included filtering variants with call rates <95% and duplicated QC samples. The *CRP* rs1205 variant was genotyped from <u>both</u> the SHFS (N=1,666) and SHS (N=2,114) participants, providing a total of (N=3,780) rs1205 genotypes. This is presented graphically in Figure 1. Except for rs1205 and rs8176746,

- 162 genotypic data from other variants were available from either the SHFS or the SHS
- 163 participants (Table 1).
- 164 Figure 1. Venn diagram illustrating relationship between analysis cohorts.



165

Although two different genotyping platforms were used for the SHS and SHFS participants, the genotyping for both was conducted in the same laboratory at Texas Biomedical Research Institute in San Antonio, Texas. All 121 participants genotyped for rs1205 and the ABO variant rs8176746 on both platforms and meeting the criteria for inclusion in the study had concordant genotyping.

171

172 Statistical analysis methods

173 Descriptive statistics presented counts and percentages for discrete variables 174 and means with standard deviations for continuous variables. Between-group

comparison of continuous variables used T-tests and assumed independent samples.
 Discrete variables utilized Pearson chi-square comparisons between groups.

Logistic regression models were developed for both univariate and multivariate 177 analysis of COVID-19 associated death or hospitalization during the observation period 178 (2/1/20 through 3/29/22). Only a single COVID-event was counted for each participant. 179 To select covariates included in the final multivariate model, BMI and any history of 180 CVD were chosen on the basis of apparent independent association (p<0.05) when all 181 182 available covariates (sex, body mass index (BMI), hypertension, diabetes mellitus (DM), impaired fasting glucose (IFG) or normal fasting glucose (NFG), history of CVD event, 183 (tobacco (current, ever, never), serum creatinine, and hemoglobin A1c (HgbA1c)) were 184 185 considered jointly. Age, sex and center were deemed important, standard adjustments 186 and therefore kept in models. The covariate related to diabetes and dysglycemia was not independently associated with COVID-19 when included with BMI (as seen in the 187 first section of Table 5), so was not retained in the final logistic model. The serum 188 hsCRP was not included as a covariate, given we were testing CRP genetic variants 189 with known effects on serum levels. Significance was accepted at a p-value of 0.05. 190 since the genetic variants were chosen on the basis of a priori evidence of potential 191 192 association with COVID-19 as well as recognizing the hypothesis driven nature of the presented analysis. 193

The SHFS cohort enrolled large families, and therefore we accounted for the 194 relatedness using random effects of pedigree relationships (established with 195 participants at recruitment) in generalized linear mixed models implemented in 196 197 SOLAR.[52,53] For discrete phenotypes such as affection status, SOLAR employs a classic liability model.[54] Briefly: the unmeasured, presumed multifactorial, basis of 198 liability to disease is modeled as a standard normal distribution (mean=0, SD=1), with 199 affected individuals represented by an upper tail of the distribution that has the same 200 density as the incidence of affection status in the general population. For this study we 201 used the mean weekly incidence of COVID-19 in the US population during the study 202 period (217.72 cases/100,000 population, 0.218%)[55] Heritability of liability is 203 204 estimated from genetic correlations between relatives[56] and the effects of measured factors (age, sex, etc., as well as measured genotypes) are estimated as deviations of 205 the liability threshold from the population incidence. 206

207 Ethics Statement

All participants in this study have provided written, informed consent to allow 208 genetic and other research related to CVD and its risk factors. Consent was obtained at 209 least once in all cases since Phase I of SHS in 1988, and in most instances has been 210 renewed during each the 6 subsequent phases until the present. Approval has been 211 obtained from the following institutional review boards (IRB) of record: Arizona Area 212 Indian Health Service IRB, MedStar Health Research Institute IRB, Great Plains Area 213 214 Indian Health Service IRB, Oglala Sioux Tribe Research Review Board, University of Oklahoma Health Sciences IRB, and Oklahoma Area Indian Health Service IRB. In 215

- addition to these formal, IRB approvals, all of the participants' Tribal governments have
- approved the conduct of the SHS/SHFS studies for these purposes. The close
- association between CVD (especially stroke) and COVID-19 infection, often in a
- bidirectional manner, justified IRB approval for this substudy.

220 **Results**

- Table 1 shows the genotyped variants selected, their associated genes and allele
- frequencies in the SHFS or SHS cohorts. The characteristics of both the SHS and
- SHFS cohorts are summarized in Table 2.

Table 2. Demographic and clinical measures stratified by enrolled cohort.

	SHFS	SHS	Total	P value
Participants, N (%)	1666 (44.1)	2114 (55.9)	3780 (100)	
Male Sex, N (%)	660 (39.6)	916 (43)	1576 (42)	.021*
Mean Age (SD), years on 2/1/2020	52.0 (14.8)	83.9 (8.4)	69.8 (19.7)	<.001**
Mean Age (SD), years at last clinical exam	41.7 (14.6)	62.9 (8.7)	53.6 (15.7)	<.001
Diabetes status, N, (%)				<.001
Diabetes Mellitus (DM)	214 (13)	1001 (49)	1215 (33)	
Impaired fasting glucose tolerance (IFG)	347 (21)	500 (24)	847 (23)	
Normal fasting glucose tolerance (NFG)	1080 (65)	563 (27)	1643 (44)	
Hypertension, N (%)	470 (28)	1110 (53)	1580 (42)	<.001
Cardiovascular disease*** N, (%)	169 (10)	870 (41)	1039 (28)	<.001
Mean BMI (SD), kg/m2	32.3 (7.7)	30.3 (6.5)	31.2 (7.1)	<.001
Current smoker N (%)	644 (39)	618 (30)	1310 (35)	0.657∆

Ever smoker, N (%)	391 (24)	749 (37)	1140 (31)	<.001
Never smoker, N (%)	619 (37)	618 (29)	1237 (34)	
Mean serum creatinine (SD), mg/dL	0.87 (0.36)	1.14 (1.22)	1 (0.90)	<.001
Mean % HgB A1c (SD)	6.36 (1.6)	7.10 (2.22)	6.90 (2.10)	<.001
Mean hsCRP (SD)****	4.12 (3.58)	4.35 (3.31)	4.23 (3.45)	.074
COVID-19 any case, N (%)	48 (2.9)	43 (2.0)	91 (2.4)	0.09
COVID-19 death, N (%)	21 (1.3)	26 (1.2)	47 (1.2)	0.93

Participants with either fatal or non-fatal COVID

	SHFS	SHS	Total	P value
Male sex, N (%)	18 (37)	15 (35)	33 (36)	0.796
Mean Age (SD), years on 2/1/2020	61.9 (14.7)	78.1 (5.0)	69.6 (13.8)	<0.001
DM/IFG/NFG, N (%)	19/5/23 (40.4,10.6,48.9)	17/13/13 (39.5,30.2,30.2)	36/18/36 (40.0, 20.0,40.0)	0.043
HTN, N (%)	22 (45.8)	21 (48.8)	43 (47.3)	0.774
CVD, N (%)	13 (27.1)	25 (58.1)	38 (41.8)	0.003
Mean BMI (SD)	36.07 (9.10)	31.04 (6.64)	33.7 (8.38)	0.001
Smoking Current/ever/never (%)	15/15/18 (31.3,31.3,37.5)	14/11/18 (32.6,25.6,41.9)	29/26/36 (31.9,28.6,39.6)	0.828
Serum Creatinine (SD), mg/dL	0.85 (0.20)	1.12 (1.86)	0.98 (1.27)	0.362
Mean HgbA1c (SD), %	7.44 (2.14)	6.65 (1.74)	7.00 (1.95)	0.191

Mean hsCRP (SD), mg/L****	5.00 (3.78)	4.48 (3.40)	4.76 (3.60)	0.715
------------------------------	-------------	-------------	-------------	-------

225 Values are mean (SD) or N (%). * Pearson chi square test for count data. **T-

test for mean (SD) data *** Any history of coronary heart disease, stroke, congestive

heart failure, or other cardiovascular disease Δ smoking "current" vs smoking "never" $\Delta\Delta$

smoking "ever" vs smoking "never" **** hsCRP values >15mg/L excluded

229

Unadjusted results limited to the primary variant of interest from the SHFS, the SHS cohort or combined SHFS/SHS cohorts, using additive and dominant models based on risk or non-risk alleles are shown in Table 3.

233

Table 3. Primary results of interest, rs1205: univariant associations with either

235fatal or non-fatal COVID-19.

Cohort	SNP	Risk allele	Model	Chi- square p value*	OR**	95% CI	P value
SHS	rs1205	С	Add	0.564	0.922	0.603 - 1.411	0.709
SHS	rs1205	С	C-DOM	0.815	1.084	0.553 - 2.124	0.815
SHS	rs1205	Т	T-DOM	0.368	1.452	0.642 - 3.285	0.370
SHFS	rs1205	С	Add	0.039	0.599	0.396 - 0.906	0.015
SHFS	rs1205	С	C-DOM	0.099	0.609	0.336 - 1.104	0.102
SHFS	rs1205	Т	T-DOM	0.016	2.976	1.171 - 7.565	0.022
SHS/SHFS	rs1205	С	Add	0.066	0.743	0.553 - 0.998	0.049
SHS/SHFS	rs1205	С	C-DOM	0.332	0.804	0.516 - 1.251	0.333
SHS/SHFS	rs1205	Т	T-DOM	0.020	2.038	1.105 - 3.758	0.023

236

237

* Pearson chi-square, asymptotic significance, two-sided

238

** OR: univariate logistic regression odds ratio

239

Results for the remaining variants are found in Supplemental Table S1. For
 variants with low frequency, logistic models were often unstable and not reported.
 Analyses in the SHFS cohort showed nominally significant associations for the rs1205 T
 allele dominant (T-Dom) genotype in the combined SHFS/SHS cohort and both additive

- and T-Dom models in the SHFS cohort).
- Table 4 shows the distribution of COVID-19 cases among recruitment centers,
- highlighting the relatively larger number of cases identified in the Dakota center

compared to other centers, and provides the allelic prevalence of rs1205 by center.

- Among the combined SHFS/SHS cohorts, the prevalence of the rs1205 T allele was 248
- 0.525 (95% CI 0.51 0.54). 249
- 250

Table 4. Combined SHFS/SHS participant and SNP results from adjusted analysis 251

by recruitment center. 252

Center*	AZ	DK	OK	p value	analysis
Ν	488	1705	1587		
Age mean (SD)	70.65 (19.48)	68.39 (20.29)	71.13 (19.05)	<0.001	1
Male sex N (%)	184 (38)	734 (43)	658 (41)	0.104	2
BMI mean (SD)	34.78 (9.88)	30.25 (6.36)	31.15 (6.55)	<0.001	1
ANY CVD_YN N(%)	119 (24)	547 (32)	373 (23)	<0.001	2
SHFS cohort N(%)	165 (34)	698 (44)	803 (47)	<0.001	2
Fatal/non-fatal	11 (12.1)	62 (68.1)	18 (19.8)	<0.001	2
COVID-19					
N (% of total)					
Risk of outcome	2.25%	3.64%	1.13%		3
% (95% CI)	(0.94-3.57)	(2.75-4.52)	(0.61-1.66)		
rs1205,C allele count	0.48	0.58	0.48	<0.001	4
(95% CI)	(0.45 - 0.51)	(0.56 - 0.59)	(0.47 - 0.50)		
rs1205 T-Dom	0.72	0.81	0.73	<0.001	2
(95% CI)	(0.68 - 0.76)	(0.79 - 0.83)	(0.71 - 0.75)		
rs1205 T-Dom	0.254	0.333	0.147		5
p value					

- * AZ = Arizona, DK = Dakotas, OK = Oklahoma centers 253
- 1= Independent samples, T-test 254
- 255 2= between center Pearson chi-square p value, 3X2 table
- 3= within center binomial confidence interval on proportion 256
- 257 4= between center Pearson chi-square p value, 3X3 table
- 258 5= within center COVID fatal/non-fatal outcome via logistic regression adjusted for age, sex, BMI, ANY_CVD
- 259
- 260
- 261
- 262
- Multivariate logistic regression model findings for the primary SNPs of interest 263
- are reported in Table 5. Results of the rs1205 T-Dom model is attenuated after 264
- adjustment for covariates, but retains nominally significant association (OR 1.859, 95%) 265
- CI 1.001-3.453, p=0.049) with COVID-19 in the combined SHS/SHFS cohorts. Within 266

- the younger SHFS cohort, the same model showed an odds ratio of 2.857, 95%CI
- 268 1.108-7.362, p=0.030.
- 269

Table 5. Results of multivariate adjusted models evaluating the composite

outcome of either fatal or non-fatal COVID-19 within the combined SHFS and SHS
 cohorts.

SHFS and SHS COMBINED						
				95%	6 CI	
Multivariate mod	el	N	OR	Lower	Upper	P value
including:						
Age		3780	0.999	0.987	1.012	0.923
Sex		3780	0.817	0.527	1.267	0.367
AZ center		3780	Indicato	r variable		
DK center		3780	2.132	1.064	4.272	0.033
OK center		3780	0.649	0.296	1.423	0.280
BMI		3780	1.050	1.023	1.079	<0.001
ANY CVD (Y/N)		3780	1.871	1.153	3.036	0.011
		SHFS C	OHORT			
				95%	6 CI	
SNP*	model	N	OR	Lower	Upper	P value
rs1205	C-Add	1647	0.587	0.381	0.905	0.016
rs1205	T-DOM	1647	2.857	1.108	7.362	0.030
		SHS CO	DHORT			
rs1205	C-Add	2042	1.057	0.683	1.634	0.804
rs1205	T-DOM	2042	1.243	0.541	2.860	0.608
SHFS and SHS COMBINED						
rs1205	C-Add	3689	0.799	0.592	1.078	0.142
rs1205	T-DOM	3689	1.859	1.001	3.453	0.049

²⁷³

* Genetic variant included in model adjusted for age, sex, center, BMI, and ANY CVD.

274

In the SHFS analysis, using a generalized linear threshold model in SOLAR to
adjust for the random effect of family relatedness, and adjusting for fixed effects of sex,
age, BMI, CVD, and center, either fatal or non-fatal COVID-19 was significantly
associated with the fixed effect of the rs1205 T allele-dominant genotype (p=0.0003).
The regression beta for this association was negative (= -0.50 standard deviations),
indicating a tendency to increase the affected upper tail of the liability distribution (thus
confirming rs1205-T Dom genotype as a risk allele).

282

While those with rs1205 T-Dom genotypes trended toward lower mean hsCRP levels at baseline than others (p=0.087 excluding levels over 15 mg/L to avoid spurious elevations due to intercurrent infections), mean hsCRP levels were not significantly different between COVID-19 cases or controls. (Supplemental Table S2).

287

288 Discussion

We present previously unreported evidence of association between a common 289 human variant (rs1205) and the clinical impact of the SARS-CoV-2 virus causing 290 COVID-19. While our study has a modest number of cases, these results derive from a 291 large cohort of American Indian individuals who are being followed longitudinally using 292 standardized, physician review of medical records[4] The rs1205 variant has been 293 recognized as functionally affecting serum levels of CRP.[25,28,29] in several 294 295 populations and, in the present SHFS population as well.[50] CRP is an important component of the innate immune system, thus supporting a role of the gene and this 296 297 variant's potential effects on the pathophysiology of COVID-19. A genome-wide association meta-analysis has reported an intron variant (rs67579710) associated with 298 299 COVID-19 hospitalization among 24,741 cases and 2,835,201 controls. [42] This variant 300 is 4.5Mb from rs1205 [57] and within the thrombospondin3 gene, thus it may play a role in the thrombosis associated with COVID-19, rather than inflammatory pathways. 301

There are ample theoretical reasons that heritable genetic variation could affect 302 303 SARS-CoV-2 infection, beginning with the viral requirement for surface receptors to gain 304 entry to the cytoplasm[58] and running through multiple immune response pathways 305 generating the "cytokine storm" which has been prominently noted in the pathogenesis of COVID-19.[59] A number of genetic variants have been associated with morbidity 306 and mortality, including variants in the angiotensin converting enzyme 1 (ACE1) 307 gene,[60] the TMPRSS2 gene,[61] the IL-6 gene[62] and others extensively reviewed by 308 Ishak et al.[63] The COVID-19 Host Genetics Initiative, a massive ascertainment of 309 nearly 50,000 cases from 19 countries has identified 13 genome-wide loci related to 310 either initial infection, or morbidity.[64] 311

312 The rs1205 variant is a C/T single nucleotide polymorphism in the 3' untranslated region of the C-reactive protein gene (CRP), with a prevalence of the C allele ranging 313 from ~ 0.67 in European populations, to ~ 0.40 in Asian populations, [65] and 0.51 to 314 0.54 in the present study. The 4 CRP variants were chosen for their role in the innate 315 immune system and availability in the SHS dataset, but no literature was found that 316 examined CRP variants related to COVID-19 severity, perhaps because CRP has 317 traditionally been viewed as a biomarker and not as a potential causal factor. There are, 318 319 however, reports of CRP variants associated with the clinical outcomes of other infections[22,23] and the response to vaccination.[26] Additionally, reduced expression 320 of serum CRP is consistently reported associated with the rs1205 T allele, with the beta 321 coefficient for each additional T allele ranging between -0.17 and -0.27;[25,28,29] and 322 estimated at -0.23 in the SHS Dakota center.[50] As noted in Table S2 the mean serum 323 CRP level is lower in the present study, among those with the rs1205 T-Dom genotype 324 compared with those homozygous for the C allele, although the difference is not 325 326 significant.

Although the prevalent view of COVID-19 pathophysiology implicates a hyperactive immune response (often characterized by increased CRP serum levels as well as coordinated production of other cytokines), it also seems plausible that a relative, baseline insufficiency of an innate immune factor, particularly in the early phase of exposure, could also result in increased morbidity.

CRP genotypes correlating with increased baseline CRP levels have been positively associated with risk of pre-eclampsia[46,47,66] and conversely, as in the current study, *CRP* genotypes (including rs1205 T-Dom) correlated with lower CRP levels have been associated with increased infectious burden.[22-24] These divergent effects invite speculation that *CRP* polymorphisms may have experienced balanced selection during evolution.

338 Our multivariate logistic regression results are in accord with prior studies that 339 showed the contribution of commonly reported clinical factors, such as age,[67] BMI[64] 340 and pre-existing CVD,[68,69] which negatively impact COVID-19 outcomes. Although the mean BMI of the SHFS is somewhat greater than the SHS cohort, it should be noted 341 342 that the SHFS cohort has a low prevalence of DM (13%) and is younger than the SHFS, 343 due to selection for that substudy of those without diabetes at baseline. Perhaps this allows a clearer genetic (vs an acquired clinical or environmental) association to 344 become apparent. 345

The small number of cases when stratified by Center suggests cautious 346 interpretation, but is presented since the number of cases from the Dakota Center is 347 considerably higher than from the comparable Oklahoma center. Although the 348 possibility of population stratification confounding our results is present, we believe the 349 fact that all 3 centers show an effect of the T-Dom genotype in the same direction, 350 including the Arizona Center, which is likely to be most distant in their genetic 351 background, suggests genetic background effects are not likely. The statistical 352 significance of the center covariate could be due to various differences in regional, 353 354 environmental factors, such as household density, weather, and accessibility of medical 355 care.

The lack of significant results in the other SNPs is not surprising, given the number of these variants with low allele frequencies and the small number of COVID-19 cases. Further surveillance of the SHS cohort will likely identify new cases and improve the power for other variants (eg rs111837807 and rs2109069).

The limitations of this analysis are chiefly related to the relatively small number of cases obtained to this point. The morbid case ascertainment is subject to undercounting since the choice of medical records for review is based primarily on CVD outcomes. This does not affect ascertainment of mortal cases, since all deaths are reviewed and recorded as soon as possible. The possibility of population stratification is noted, although seems unlikely for reasons noted above. P values have not been adjusted for multiple testing. The study's strengths include a robust physician assignment of outcomes using medical records and comprehensive analysis of genetic variabilities as well as adjustment for relatedness between individuals.

370 It is clear that race/ethnicity is a valid and critical risk marker for other underlying conditions affecting the complexity of COVID-19 disease, such as structural racism, 371 discrimination and socioeconomic status, [70] lack of health care access, [71] and 372 exposure to infectious agents related to high risk and service industry occupations.[72] 373 374 Although one can never be confident that all confounding factors have been adjusted 375 properly, Williamson et al^[2] showed that ethnicity among a very large cohort in England was associated with COVID-19 outcomes, even after adjusting for socioeconomic 376 377 factors. Thus, even though we are committed to improving our understanding of the 378 complex social and behavioral factors influencing COVID-19 disease landscape among Tribal communities we also believe that investigating the potential influence of common 379 genetic variants among the high risk American Indian/Alaska Native populations may 380 provide opportunities for therapeutic or preventive options. Although severely impacted 381 by COVID-19,[73,74] Tribal communities are, at times, excluded from scientific studies 382 due to their smaller proportion in the U.S. population and various socio-political factors. 383

In conclusion, a statistically significant association was found between the rs1205 384 T-Dom genotype and risk of COVID-19 death or hospitalization among American Indian 385 participants, employing chi-square tests, logistic regression models adjusting for age, 386 sex, center, BMI and prior history of CVD, and SOLAR software analysis also adjusting 387 for relatedness within the SHFS cohort. The direction of effect suggests a lower level of 388 389 CRP during early phases of infection may increase the risk of subsequent complications, a novel finding we will continue to investigate further as the pandemic 390 continues and our samples size tragically continues to increase. 391

392 Supporting Information:

393 Supplemental Table 1. Additional univariant associations with either fatal or non-394 fatal COVID-19.

395 Supplemental Table 2. Baseline hsCRP measures* in relation to rs1205 T-Dom 396 genotype and COVID-19 case/control status.

- 397
- 398 Acknowledgements:

We thank the study participants, Indian Health Service facilities, and participating Tribal communities for their extraordinary cooperation and involvement, which has been

401 critical to the success of the Strong Heart Study since 1988.

402 References:

403	1.	Risk for COVID-19 Infection, Hospitalization, and Death By Race/Ethnicity,
404		https://www.cdc.gov/coronavirus/2019-ncov/covid-data/investigations-
405		discovery/hospitalization-death-by-race-ethnicity.html (accessed 1/7/2022)
406	2.	Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-
407		19-related death using OpenSAFELY. Nature. 2020 Aug;584(7821):430-436. doi:
408		10.1038/s41586-020-2521-4. Epub 2020 Jul 8. PMID: 32640463; PMCID:
409		PMC7611074.
410	3.	Ferreira de Araújo JL, Menezes D, Saraiva-Duarte JM, et al. Systematic review
411		of host genetic association with Covid-19 prognosis and susceptibility: What have
412		we learned in 2020? Rev Med Virol. 2021 Aug 2:e2283. doi: 10.1002/rmv.2283.
413		Epub ahead of print. PMID: 34338380.
414	4.	Lee ET, Welty TK, Fabsitz R, Cowan LD, Le NA, Oopik AJ, et al. The Strong
415		Heart Study. A study of cardiovascular disease in American Indians: design and
416		methods. Am J Epidemiol. 1990 Dec;132(6):1141-55. PMID: 2260546.
417	5.	North KE, Howard BV, Welty TK, Best LG, Lee ET, Yeh JL, et al. Genetic and
418		environmental contributions to cardiovascular disease risk in American Indians:
419		the strong heart family study. Am J Epidemiol. 2003 Feb 15;157(4):303-14.
420		PMID: 12578801.
421	6.	Xu J, Lee ET, Peterson LE, Devereux RB, Rhoades ER, Umans JG, et al.
422		Differences in risk factors for coronary heart disease among diabetic and
423		nondiabetic individuals from a population with high rates of diabetes: the Strong
424		Heart Study. J Clin Endocrinol Metab. 2012 Oct;97(10):3766-74. doi:
425		10.1210/jc.2012-2110. Epub 2012 Jul 16. PMID: 22802089; PMCID:
426		PMC3674295.
427	7.	Lu W, Resnick HE, Jablonski KA, Jones KL, Jain AK, Howard WJ, et al. Non-
428		HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes: the
429		strong heart study. Diabetes Care. 2003 Jan;26(1):16-23. doi:
430		10.2337/diacare.26.1.16. PMID: 12502653.
431	8.	Gómez J, Albaiceta GM, Cuesta-Llavona E, García-Clemente M, López-Larrea
432		C, Amado-Rodríguez L, et al. The Interferon-induced transmembrane protein 3
433		gene (IFITM3) rs12252 C variant is associated with COVID-19. Cytokine. 2021
434		Jan;137:155354. doi: 10.1016/j.cyto.2020.155354. Epub 2020 Oct 23. PMID:
435		33113474.
436	9.	Zhang Q, Bastard P, Liu Z, Le Pen J, Moncada-Velez M, et al. Inborn errors of
437		type I IFN immunity in patients with life-threatening COVID-19. Science. 2020
438		Oct 23;370(6515):eabd4570. doi: 10.1126/science.abd4570. Epub 2020 Sep 24.
439		PMID: 32972995; PMCID: PMC7857407.
440	10	. Kuo CL, Pilling LC, Atkins JL, Masoli JAH, Delgado J, Kuchel GA, et al. APOE e4
441		Genotype Predicts Severe COVID-19 in the UK Biobank Community Cohort. J
442		Gerontol A Biol Sci Med Sci. 2020 Oct 15;75(11):2231-2232. doi:
443		10.1093/gerona/glaa131. PMID: 32451547; PMCID: PMC7314139.
444	11	Latini A, Agolini E, Novelli A, Borgiani P, Giannini R, Gravina P, et al. COVID-19
445		and Genetic Variants of Protein Involved in the SARS-CoV-2 Entry into the Host
446		Cells. Genes (Basel). 2020 Aug 27;11(9):1010. doi: 10.3390/genes11091010.
447		PMID: 32867305; PMCID: PMC7565048.

448	12. Ghafouri-Fard S, Noroozi R, Vafaee R, Branicki W, Pospiech E, Pyrc K, et al.
449	Effects of host genetic variations on response to, susceptibility and severity of
450	respiratory infections. Biomed Pharmacother. 2020 Aug;128:110296. doi:
451	10.1016/j.biopha.2020.110296. Epub 2020 May 29. PMID: 32480226; PMCID:
452	PMC7258806.
453	13. Jafarpour R, Pashangzadeh S, Dowran R. Host factors: Implications in
454	immunopathogenesis of COVID-19. Pathol Res Pract. 2021 Dec;228:153647.
455	doi: 10.1016/j.prp.2021.153647. Epub 2021 Oct 12. PMID: 34749207; PMCID:
456	PMC8505027
457	14. Saulle I, Vicentini C, Clerici M, Biasin M. Antigen presentation in SARS-CoV-2
458	infection: the role of class I HLA and ERAP polymorphisms. Hum Immunol. 2021
459	Aug;82(8):551-560. doi: 10.1016/j.humimm.2021.05.003. Epub 2021 May 10.
460	PMID: 34116863; PMCID: PMC8108382.
461	15. Littera R, Campagna M, Deidda S, Angioni G, Cipri S, Melis M, et al. Human
462	Leukocyte Antigen Complex and Other Immunogenetic and Clinical Factors
463	Influence Susceptibility or Protection to SARS-CoV-2 Infection and Severity of
464	the Disease Course. The Sardinian Experience. Front Immunol. 2020 Dec
465	4;11:605688. doi: 10.3389/fimmu.2020.605688. PMID: 33343579; PMCID:
466	PMC7746644.
467	16. Gómez J, Albaiceta GM, García-Clemente M, García-Gala JM, Coto E. DNA
468	genotyping of the ABO gene showed a significant association of the A-group
469	(A1/A2 variants) with severe COVID-19. Eur J Intern Med. 2021 Jun;88:129-132.
470	doi: 10.1016/j.ejim.2021.02.016. Epub 2021 Feb 25. PMID: 33750629; PMCID:
471	PMC7906510.
472	17. Pereira E, Felipe S, de Freitas R, Araújo V, Soares P, Ribeiro J, et al. ABO blood
473	group and link to COVID-19: A comprehensive review of the reported
474	associations and their possible underlying mechanisms. Microb Pathog. 2022
475	Jun 25;169:105658. doi: 10.1016/j.micpath.2022.105658. Epub ahead of print.
476	PMID: 35764188; PMCID: PMC9233352.
477	18. Tamayo-Velasco Á, Peñarrubia-Ponce MJ, Álvarez FJ, de la Fuente I, Pérez-
478	González S, Andaluz-Ojeda D. ABO Blood System and COVID-19 Susceptibility:
479	Anti-A and Anti-B Antibodies Are the Key Points. Front Med (Lausanne). 2022
480	Apr 25;9:882477. doi: 10.3389/fmed.2022.882477. PMID: 35547235; PMCID:
481	PMC9081929.
482	19. https://www.covid19hg.org, accessed 3/1/23.
483	20. de Araújo JLF, Menezes D, de Aguiar RS, de Souza RP. IFITM3, FURIN, ACE1,
484	and $TNF-\alpha$ Genetic Association With COVID-19 Outcomes: Systematic Review
485	and Meta-Analysis. Front Genet. 2022 Apr 1;13:775246. doi:
486	10.3389/fgene.2022.775246. PMID: 35432458; PMCID: PMC9010674.
487	21. Gkouskou K, Vasilogiannakopoulou T, Andreakos E, Davanos N, Gazouli M,
488	Sanoudou D, et al. COVID-19 enters the expanding network of apolipoprotein E4-
489	related pathologies. Redox Biol. 2021 May;41:101938. doi:
490	10.1016/j.redox.2021.101938. Epub 2021 Mar 10. PMID: 33730676; PMCID:
491	PMC7943392.
492	22. Liu C, Jin P, Luo Y, Xu J, Kong C, Chen J, et al. Association of Single-Nucleotide
493	Polymorphisms of C-Reactive Protein Gene with Susceptibility to Infantile Sepsis

494	in Southern China. Med Sci Monit. 2018 Jan 30;24:590-595. doi:
495	10.12659/msm.908602. PMID: 29379005: PMCID: PMC5800323.
496	23. Chou SC. Ko HW. Lin YC. CRP/IL-6/IL-10 Single-Nucleotide Polymorphisms
497	Correlate with the Susceptibility and Severity of Community-Acquired
498	Pneumonia, Genet Test Mol Biomarkers, 2016 Dec:20(12):732-740, doi:
499	10.1089/gtmb.2016.0156. Epub 2016 Oct 5. Erratum in: Genet Test Mol
500	Biomarkers, 2019 Jun;23(6);433, PMID; 27705004.
501	24. Ponasenko AV, Kutikhin AG, Khutornava MV, Rutkovskava NV, Kondvukova NV,
502	Odarenko YN, et al. Inherited Variation in Cytokine. Acute Phase Response, and
503	Calcium Metabolism Genes Affects Susceptibility to Infective Endocarditis.
504	Mediators Inflamm. 2017:2017:7962546. doi: 10.1155/2017/7962546. Epub 2017
505	Jun 4. PMID: 28659664: PMCID: PMC5474236.
506	25. Kocarnik JM, Pendergrass SA, Carty CL, Pankow JS, Schumacher FR, Cheng I,
507	et al. Multiancestral analysis of inflammation-related genetic variants and C-
508	reactive protein in the population architecture using genomics and epidemiology
509	study. Circ Cardiovasc Genet. 2014 Apr; 7(2):178–88. https://doi.
510	org/10.1161/CIRCGENETICS.113.000173 Epub 2014 Mar 12. PMID: 24622110;
511	PubMed Central PMCID: PMC4104750.
512	26. Ovsyannikova IG, White SJ, Larrabee BR, Grill DE, Jacobson RM, Poland GA.
513	Leptin and leptin-related gene polymorphisms, obesity, and influenza A/H1N1
514	vaccine-induced immune responses in older individuals. Vaccine. 2014 Feb
515	7;32(7):881-7. doi: 10.1016/j.vaccine.2013.12.009. Epub 2013 Dec 18. PMID:
516	24360890; PMCID: PMC3922536.
517	27. Mölkänen T, Rostila A, Ruotsalainen E, Alanne M, Perola M, Järvinen A. Genetic
518	polymorphism of the C-reactive protein (CRP) gene and a deep infection focus
519	determine maximal serum CRP level in Staphylococcus aureus bacteremia. Eur
520	J Clin Microbiol Infect Dis. 2010 Sep;29(9):1131-7. doi: 10.1007/s10096-010-
521	0978-z. Epub 2010 Jun 16. PMID: 20552244.
522	28. Ridker PM, Pare G, Parker A, Zee RY, Danik JS, Buring JE, et al. Loci related to
523	metabolic-syndrome pathways including LEPR, HNF1A, IL6R, and GCKR
524	associate with plasma C-reactive protein: the Women's Genome Health Study.
525	Am J Hum Genet. 2008 May; 82(5):1185–92. https://doi.org/10.
526	1016/j.ajhg.2008.03.015 Epub 2008 Apr 24. PMID: 18439548; PubMed Central
527	
528	29. Wang S, Xu H, Zhou N, Zhao W, Wu D, Shen B. Combined Effects of Single
529	Nucleotide Polymorphisms (SNPs) within C-reactive Protein (CRP) and
530	Environmental Parameters on Risk and Prognosis for Diabetic Foot
531	Osteomyelitis Patients. Exp Clin Endocrinol Diabetes. 2020 Aug;128(8):528-539.
532	001. 10.1055/a-0754-5622. Epub 2020 Jun 15. PMID: 32542640.
533	30. Myburgh PH, Nienaber-Rousseau C, Kruger IM, Towers GW. Education,
534	Sinoking and CRP Genetics in Relation to C-Reactive Protein Concentrations in Reak South Africana, Int. I Environ Dea Dublic Health, 2020 Son 11:17(19):6646
535	diack South Anicans. Int J Environ Res Public Fiedlin. 2020 Sep 11,17(18):0040.
530	UUI. 10.3390/IJELPITT 100040. FIVID. 32933000, FIVIDD. FIVID7338133.
53/ E20	and Aging Desearch in Conomic Enidemiology: National Hoart Lung, and Place
238 520	Institute CO Example Sequencing Project Association of example sequences with
222	

plasma C-reactive protein levels in >9000 participants. Hum Mol Genet. 2015 Jan 540 15; 24(2):559–71. https://doi.org/10.1093/hmg/ddu450 Epub 2014 Sep 3. PMID: 541 25187575; PubMed Central PMCID:PMC4334838. 542 32. Mohammadpour S, Torshizi Esfahani A, Halaji M, Lak M, Ranjbar R. An updated 543 review of the association of host genetic factors with susceptibility and resistance 544 to COVID-19. J Cell Physiol. 2021 Jan;236(1):49-54. doi: 10.1002/jcp.29868. 545 Epub 2020 Jun 15. PMID: 32542735; PMCID: PMC7323230. 546 33. Saulle I, Vanetti C, Goglia S, Vicentini C, Tombetti E, Garziano M, et al. New 547 ERAP2/Iso3 Isoform Expression Is Triggered by Different Microbial Stimuli in 548 Human Cells. Could It Play a Role in the Modulation of SARS-CoV-2 Infection? 549 550 Cells. 2020 Aug 24;9(9):1951. doi: 10.3390/cells9091951. PMID: 32847031; PMCID: PMC7563522. 551 34. D'Amico S, Tempora P, Lucarini V, Melaiu O, Gaspari S, Algeri M, et al. ERAP1 552 and ERAP2 Enzymes: A Protective Shield for RAS against COVID-19? Int J Mol 553 Sci. 2021 Feb 8;22(4):1705. doi: 10.3390/ijms22041705. PMID: 33567739; 554 PMCID: PMC7914632. 555 35. Karcioglu Batur L, Hekim N. Correlation between interleukin gene polymorphisms 556 and current prevalence and mortality rates due to novel coronavirus disease 557 2019 (COVID-2019) in 23 countries. J Med Virol. 2021 Oct;93(10):5853-5863. 558 559 doi: 10.1002/jmv.27127. Epub 2021 Jun 10. PMID: 34081354; PMCID: PMC8242628. 560 36. Smieszek SP, Przychodzen BP, Polymeropoulos VM, Polymeropoulos CM, 561 Polymeropoulos MH. Assessing the potential correlation of polymorphisms in the 562 IL6R with relative IL6 elevation in severely ill COVID-19 patients'. Cytokine. 2021 563 Dec;148:155662. doi: 10.1016/j.cyto.2021.155662. Epub 2021 Jul 29. Erratum in: 564 Cytokine. 2022 Jan;149:155752. PMID: 34353696; PMCID: PMC8318728. 565 37. Severe Covid-19 GWAS Group; Ellinghaus D, Degenhardt F, Bujanda L, Buti M, 566 Albillos A. Invernizzi P. et al. Genomewide Association Study of Severe Covid-19 567 with Respiratory Failure. N Engl J Med. 2020 Oct 15;383(16):1522-1534. doi: 568 10.1056/NEJMoa2020283. Epub 2020 Jun 17. PMID: 32558485; PMCID: 569 PMC7315890. 570 38. Kolin DA, Kulm S, Christos PJ, Elemento O. Clinical, regional, and genetic 571 572 characteristics of Covid-19 patients from UK Biobank. PLoS One. 2020 Nov 17;15(11):e0241264. doi: 10.1371/journal.pone.0241264. PMID: 33201886; 573 PMCID: PMC7671499. 574 39. Lehrer S, Rheinstein PH. ABO blood groups, COVID-19 infection and mortality. 575 Blood Cells Mol Dis. 2021 Jul;89:102571. doi: 10.1016/j.bcmd.2021.102571. 576 Epub 2021 Apr 21. PMID: 33894687; PMCID: PMC8059281. 577 578 40. Velavan TP, Pallerla SR, Rüter J, Augustin Y, Kremsner PG, Krishna S, et al. Host genetic factors determining COVID-19 susceptibility and severity. 579 EBioMedicine. 2021 Oct;72:103629. doi: 10.1016/j.ebiom.2021.103629. Epub 580 2021 Oct 13. PMID: 34655949; PMCID: PMC8512556. 581 41. Pairo-Castineira E, Clohisey S, Klaric L, Bretherick AD, Rawlik K, Pasko D, et al. 582 Genetic mechanisms of critical illness in COVID-19. Nature. 2021 583 584 Mar;591(7848):92-98. doi: 10.1038/s41586-020-03065-y. Epub 2020 Dec 11. PMID: 33307546. 585

42. https://app.covid19hg.org/variants, accessed 12/15/22. 586 43. Szyda J, Dobosz P, Stojak J, Sypniewski M, Suchocki T, Kotlarz K, et al. Beyond 587 GWAS-Could Genetic Differentiation within the Allograft Rejection Pathway 588 Shape Natural Immunity to COVID-19? Int J Mol Sci. 2022 Jun 3;23(11):6272. 589 doi: 10.3390/ijms23116272. PMID: 35682950; PMCID: PMC9181155. 590 44. Nimptsch K, Aleksandrova K, Fedirko V, Jenab M, Gunter MJ, Siersema PD, et 591 al. Pre-diagnostic C-reactive protein concentrations, CRP genetic variation and 592 mortality among individuals with colorectal cancer in Western European 593 populations. BMC Cancer. 2022 Jun 24;22(1):695. doi: 10.1186/s12885-022-594 09778-9. PMID: 35739525; PMCID: PMC9229883. 595 596 45. Pan HY, Mi YY, Xu K, Zhang Z, Wu H, Zhang W, et al. Association of C-reactive protein (CRP) rs1205 and rs2808630 variants and risk of cancer. J Cell Physiol. 597 2020 Nov;235(11):8571-8584. doi: 10.1002/jcp.29701. Epub 2020 Apr 24. PMID: 598 32329054. 599 46. Best LG, Saxena R, Anderson CM, Barnes MR, Hakonarson H, Falcon G, et al. 600 Two variants of the C-reactive protein gene are associated with risk of pre-601 eclampsia in an American Indian population. PLoS One. 2013 Aug 602 5;8(8):e71231. doi: 10.1371/journal.pone.0071231. Erratum in: PLoS One. 2013 603 Sep 23;8(9):null. PMID: 23940726; PMCID: PMC3733916. 604 605 47. Best LG, Nadeau M, Davis K, Lamb F, Bercier S, Anderson CM. Genetic variants, immune function, and risk of pre-eclampsia among American Indians. 606 Am J Reprod Immunol. 2012 Feb;67(2):152-9. doi: 10.1111/j.1600-607 0897.2011.01076.x. Epub 2011 Oct 17. PMID: 22004660; PMCID: PMC3253256. 608 48. Shara NM, Wang H, Valaitis E, Pehlivanova M, Carter EA, Resnick HE, et al. 609 Comparison of estimated glomerular filtration rates and albuminuria in predicting 610 risk of coronary heart disease in a population with high prevalence of diabetes 611 mellitus and renal disease. Am J Cardiol. 2011 Feb 1:107(3):399-405. doi: 612 10.1016/i.amicard.2010.09.036. PMID: 21257005: PMCID: PMC3035999. 613 49. Wang H, Shara NM, Lee ET, Devereux R, Calhoun D, de Simone G, et al. 614 Hemoglobin A1c, fasting glucose, and cardiovascular risk in a population with 615 high prevalence of diabetes: the strong heart study. Diabetes Care. 2011 616 Sep;34(9):1952-8. doi: 10.2337/dc11-0329. Epub 2011 Jul 25. PMID: 21788631; 617 618 PMCID: PMC3161283. 50. Best LG, Balakrishnan P, Cole SA, Haack K, Kocarnik JM, Pankratz N, et al. 619 Genetic analysis of hsCRP in American Indians: The Strong Heart Family Study. 620 PLoS One. 2019 Oct 17;14(10):e0223574. doi: 10.1371/journal.pone.0223574. 621 PMID: 31622379; PMCID: PMC6797125. 622 51. Voight BF, Kang HM, Ding J, et al. The metabochip, a custom genotyping array 623 624 for genetic studies of metabolic, cardiovascular, and anthropometric traits. PLoS Genet. 2012;8(8):e1002793. doi: 10.1371/journal.pgen.1002793. Epub 2012 Aug 625 Erratum in: PLoS Genet. 2013 Apr;9(4). doi:10.1371/annotation/0b4e9c8b-626 627 35c5-4dbd-b95b-0640250fbc87. PMID: 22876189; PubMed Central PMCID: PMC3410907. 628 52. Almasy L, Blangero J. Multipoint quantitative-trait linkage analysis in general 629 630 pedigrees. Am J Hum Genet, 1998. 62:1198-1211. 53. https://solar-eclipse-genetics.org 631

54. Falconer DS, Mackay FC. Introduction to Quantitative Genetics, 4th ed. Harlow: 632 Prentice Hall. pp. 299-309. 633 55. US CDC. COVID data tracker: weekly case trends – the United States. 634 https://covid.cdc.gov/covid-data-tracker/#datatracker-home . Accessed 635 10/24/2022. 636 56. Williams JT, Blangero J. Power of variance component linkage analysis – II. 637 Discrete traits. Ann Hum Genet, 2004. 68:620-632. 638 57. http://genome.ucsc.edu/, accessed 12/15/22 639 58. Sturrock BR, Milne KM, Chevassut TJ. The renin-angiotensin system - a 640 therapeutic target in COVID-19? Clin Med (Lond). 2020 Jul;20(4):e72-e75. doi: 641 642 10.7861/clinmed.2020-0146. Epub 2020 May 15. PMID: 32414711; PMCID: PMC7385758. 643 59. Rasmi Y. Hatamkhani S. Naderi R. Shokati A. Naveb Zadeh V. Hosseinzadeh F. 644 et al. Molecular signaling pathways, pathophysiological features in various 645 organs, and treatment strategies in SARS-CoV2 infection. Acta Histochem. 2022 646 Jul;124(5):151908. doi: 10.1016/j.acthis.2022.151908. Epub 2022 May 25. PMID: 647 35662001; PMCID: PMC9130726. 648 60. Saad H, Jabotian K, Sakr C, Mahfouz R, Akl IB, Zgheib NK. The Role of 649 Angiotensin Converting Enzyme 1 Insertion/Deletion Genetic Polymorphism in 650 the Risk and Severity of COVID-19 Infection. Front Med (Lausanne). 2021 Dec 651 23;8:798571. doi: 10.3389/fmed.2021.798571. PMID: 35004773; PMCID: 652 PMC8733297. 653 61. Rokni M. Heidari Nia M. Sarhadi M. Mirineiad S. Sargazi S. Moudi M. et al. 654 Association of TMPRSS2 Gene Polymorphisms with COVID-19 Severity and 655 Mortality: a Case-Control Study with Computational Analyses. Appl Biochem 656 Biotechnol. 2022 Aug;194(8):3507-3526. doi: 10.1007/s12010-022-03885-w. 657 Epub 2022 Apr 7. PMID: 35386063; PMCID: PMC8986508. 658 62. Giannitrapani L, Augello G, Mirarchi L, Amodeo S, Veronese N, Sasso BL, et al. 659 Outcome predictors in SARS-CoV-2 disease (COVID-19): The prominent role of 660 IL-6 levels and an IL-6 gene polymorphism in a western Sicilian population. J 661 Infect. 2022 Aug;85(2):174-211. doi: 10.1016/j.jinf.2022.04.043. Epub 2022 Apr 662 29. PMID: 35490738; PMCID: PMC9050196. 663 664 63. Ishak A, Mehendale M, AlRawashdeh MM, Sestacovschi C, Sharath M, Pandav K, et al. The association of COVID-19 severity and susceptibility and genetic risk 665 factors: A systematic review of the literature. Gene. 2022 Jun 14:836:146674. 666 doi: 10.1016/j.gene.2022.146674. Epub ahead of print. PMID: 35714803; 667 PMCID: PMC9195407. 668 64. COVID-19 Host Genetics Initiative. Mapping the human genetic architecture of 669 670 COVID-19. Nature. 2021 Dec;600(7889):472-477. doi: 10.1038/s41586-021-03767-x. Epub 2021 Jul 8. PMID: 34237774; PMCID: PMC8674144. 671 65. https://www.ncbi.nlm.nih.gov/snp/rs1205, 7/24/23. 672 66. Wang Y, Wang Q, Guo C, Wang S, Wang X, An L, et al. Association between 673 CRP gene polymorphisms and the risk of preeclampsia in Han Chinese women. 674 Genet Test Mol Biomarkers. 2014 Nov;18(11):775-80. doi: 675 676 10.1089/gtmb.2014.0142. Epub 2014 Oct 14. PMID: 25314633.

677 678 679 680 681 682 683 684 685	 67. Rod JE, Oviedo-Trespalacios O, Cortes-Ramirez J. A brief-review of the risk factors for covid-19 severity. Rev Saude Publica. 2020;54:60. doi: 10.11606/s1518-8787.2020054002481. Epub 2020 Jun 1. PMID: 32491116; PMCID: PMC7263798. 68. Dan S, Pant M, Upadhyay SK. The Case Fatality Rate in COVID-19 Patients With Cardiovascular Disease: Global Health Challenge and Paradigm in the Current Pandemic. Curr Pharmacol Rep. 2020;6(6):315-324. doi: 10.1007/s40495-020-00239-0. Epub 2020 Sep 15. PMID: 32953401; PMCID: PMC7490208
686	69 Wilk-Sledziewska K. Sielatycki P.I. Uscinska N. Buino F. Rosolowski M
687	Kakareko K, et al. The Impact of Cardiovascular Risk Factors on the Course of
688	COVID-19. J Clin Med. 2022 Apr 18;11(8):2250. doi: 10.3390/jcm11082250.
689	PMID: 35456343; PMCID: PMC9026388.
690	70. Andrasik MP, Maunakea AK, Oseso L, Rodriguez-Diaz CE, Wallace S, Walters
691	K, et al. Awakening: The Unveiling of Historically Unaddressed Social Inequities
692	During the COVID-19 Pandemic in the United States. Infect Dis Clin North Am.
693	2022 Jun;36(2):295-308. doi: 10.1016/j.idc.2022.01.009. Epub 2022 Feb 1.
694	PMID: 35636901; PMCID: PMC8806123.
695	/1. Khanijahani A, lezadi S, Gholipour K, Azami-Aghdash S, Naghibi D. A systematic
696	Health 2021 New 24:20(1):249, doi: 10.1196/c12020.021.01592.4. DMID:
6097	3/810081. DMCID: DMC8611382
600	72 Koh D. Occupational risks for COV/ID-19 infection. Occup Med (Lond), 2020 Mar
700	12:70(1):3-5 doi: 10.1093/occmed/kgaa036_PMID: 32107548; PMCID:
701	PMC7107962.
702	73. Kovich H. Rural Matters - Coronavirus and the Navajo Nation. <i>N Engl J Med</i> .
703	2020;383(2):105-107. doi:10.1056/NEJMp2012114
704	74. Cohen, P. N. (2020). The COVID-19 Epidemic in Rural U.S. Counties. European
705	Journal of Environment and Public Health, 4(2),
706	em0050. https://doi.org/10.29333/ejeph/8331
707	

708